Leukapheresis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Leukapheresis Market is projected to expand from USD 83.49 Million in 2025 to USD 114.27 Million by 2031, registering a CAGR of 5.37%. Leukapheresis is a specialized medical procedure wherein white blood cells are separated from drawn blood, while the remaining components are returned to the patient's circulation. Market growth is primarily driven by the increasing prevalence of hematological malignancies, which fuels the demand for therapeutic apheresis to manage elevated white blood cell counts, and the expansion of cell-based immunotherapy research necessitating high-quality leukopaks for the manufacturing of Advanced Therapy Medicinal Products. This clinical urgency is highlighted by recent statistics; according to the American Cancer Society, approximately 62,770 new cases of leukemia were projected to be diagnosed in the United States in 2024, underscoring the critical need for efficient cellular separation technologies to support ongoing treatment and research protocols.

Despite these robust growth drivers, the market faces a significant hurdle due to the substantial costs associated with apheresis equipment and procedures. The high capital expenditure required for automated devices, combined with the recurring expenses for disposable kits, limits accessibility for smaller healthcare facilities and creates barriers to adoption in cost-sensitive developing regions. These financial constraints effectively restrict the widespread implementation of these essential technologies, preventing smaller institutions from acquiring the necessary infrastructure to serve their patient populations.

Market Drivers

The rapid commercialization of CAR-T cell therapies acts as a primary catalyst for the global leukapheresis market, significantly increasing the utilization of apheresis systems for harvesting autologous T-cells. As regulatory bodies extend approvals for these treatments to earlier lines of therapy, manufacturing networks are compelled to scale rapidly to handle larger patient volumes, necessitating a denser infrastructure of collection centers capable of performing apheresis. This commercial momentum is reflected in the financial success of key market products dependent on these procedures; according to Johnson & Johnson's 'Q3 2024 Earnings Report' from October 2024, worldwide operational sales for Carvykti, a CAR-T therapy for multiple myeloma, rose by 87.6% year-over-year to $286 million. Such swift revenue growth indicates broadened patient access and directly correlates with a higher number of collection procedures needed to produce these personalized treatments, thereby fueling market expansion.

Concurrently, a surge in immuno-oncology and cell therapy clinical trials is substantially boosting the demand for both clinical procedures and research-grade leukopaks used in process development. Developers depend on consistent access to high-quality cellular starting materials to validate manufacturing processes and conduct safety studies for new candidates, ensuring a continuous revenue stream for apheresis providers. According to the American Society of Gene + Cell Therapy's 'Gene, Cell, + RNA Therapy Landscape Q1 2024 Quarterly Report' released in April 2024, the global pipeline has grown to include 4,021 gene, cell, and RNA therapies in development, spanning from preclinical to pre-registration stages. This extensive research activity is supported by significant federal investment, such as the National Cancer Institute's 2024 operating budget of $7.22 billion, which helps stabilize the supply chain and ensures a steady requirement for leukapheresis technologies in both clinical and laboratory settings.

Market Challenges

The significant financial burden associated with leukapheresis equipment and operational expenses serves as a major obstacle to broader market growth. Automated apheresis devices require a high capital expenditure, effectively limiting their acquisition to large, well-funded medical centers and reference laboratories. This financial threshold prevents smaller healthcare facilities and community clinics, particularly in cost-sensitive developing regions, from adopting these essential technologies, thereby restricting the overall installed base and limiting the volume of patients who can access these services.

In addition to the initial asset purchase, the market faces sustained pressure from rising recurring costs related to disposable kits and maintenance. These operational expenses directly impact the affordability of procedures and the final cost of blood products. This upward cost trajectory is confirmed by recent industry data; according to the Association for the Advancement of Blood & Biotherapies (AABB) in 2025, findings from the National Blood Collection and Utilization Survey indicated that the median price hospitals paid for apheresis-derived platelets increased by $65 per unit compared to the previous reporting cycle. Such escalating costs for apheresis-derived components place an economic strain on healthcare providers, ultimately forcing them to limit procedure volumes and hindering the widespread scalability of leukapheresis-dependent therapies.

Market Trends

The rise of portable and mobile leukapheresis units is fundamentally reshaping the market by decentralizing access to essential cellular starting materials. By deploying self-contained, mobile collection centers, providers can circumvent logistical barriers that historically restricted donor participation in remote or underserved areas. This shift enables the collection of high-quality leukopaks directly within communities, reducing the burden on patients who previously had to travel to fixed-site reference centers. This trend is illustrated by recent infrastructure developments aimed at extending the geographic reach of cell therapy supply chains; according to BioBridge Global's May 2025 press release regarding the launch of their first mobile leukapheresis center, the new unit is designed to support healthcare services across a region exceeding 63,000 square miles, significantly expanding the catchment area for immune cell collection.

Simultaneously, the adoption of closed-system automated processing platforms is influencing the market by necessitating upstream compatibility with sterile manufacturing workflows. As cell therapy developers transition from manual, open-lab procedures to fully automated ecosystems, there is a heightened requirement for leukapheresis products that integrate seamlessly with downstream bioreactors to minimize contamination risks and labor costs. This move towards automation ensures that the cellular starting material retains viability and consistency throughout the vein-to-vein process. The efficacy of such integrated systems is demonstrated by recent industry collaborations; according to a November 2025 announcement by Terumo Blood and Cell Technologies and the University of Chicago, researchers successfully expanded 10 million PBMCs to 9 billion cells in 10 days using the Quantum Flex platform, proving the scalability achievable when collection and processing technologies are effectively aligned.

Key Players Profiled in the Leukapheresis Market

• Asahi Kasei Medical Co. Ltd.
• Haemonetics Corporation
• TERUMO BCT INC.
• STEMCELL Technologies Canada Inc.
• Fresenius SE & Co. KGaA
• B. Braun SE
• Caltag Medsystems Limited
• Precision Medicine Group, LLC
• LMB Technologie GmbH
• Grifols, S.A.
• Kaneka Pharma Europe NV

Report Scope

In this report, the Global Leukapheresis Market has been segmented into the following categories:

Leukapheresis Market, by Type:

• Leukapheresis Devices
• Apheresis Devices
• Leukapheresis Columns
• Cell Separators
• Leukoreduction Filters
• Leukapheresis Disposables

Leukapheresis Market, by Application:

• Research Applications
• Therapeutic Applications

Leukapheresis Market, by End User:

• Blood Component Providers and Blood Centers
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Hospitals
• Transfusion Centers

Leukapheresis Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Leukapheresis Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.